DSGN Q2 2024 Earnings — Design Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DSGNDesign Therapeutics, Inc.

$569M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$151,000

Operating Income

-$15M

Net Income

-$12M

EPS (Diluted)

$-0.21

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$270M

Total Liabilities

$8M

Stockholders' Equity

$261M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$151,000	$0	—
Operating Income	-$15M	-$23M	+33.4%
Net Income	-$12M	-$20M	+40.8%